Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin–specific clinical impact

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Assessing the significance of chromosomal aberrations in cancer: Methodology and application to gliomaOriginal Research · 2007 · 1,097 citations
2. 2Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissueClinical Trial · 2014 · 627 citations
3. 3MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapyCohort Study · 2013 · 229 citations
4. 4Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCLCohort Study · 2016 · 189 citations
5. 5Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and PrednisonePrognostic Study · 2012 · 692 citations